Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that affects more than five million people worldwide. It is characterized by the immune system recognizing and attacking the body’s own tissues, leading to widespread inflammation and damage in various organs. SLE is a complex and heterogeneous condition, making it challenging to treat. These challenges carry into clinical trials where multiple organ involvement results in different composite scores—which makes the choice of patient population, drug mechanism of action, and deciding which composite score is most representative of patient benefit a very complex, multi-dimensional puzzle. Quantitative systems pharmacology (QSP) is becoming a mainstream tool that can be used to develop a holistic view of the mechanistic understanding of SLE along with available data from both pre-clinical studies and clinical trials. In this webinar, Dr. Kathleen Morgan-Kehr, Associate Director of QSP, discusses how a license-ready QSP model of SLE can be used to explore different trial designs, patient subgroups, and a variety of dose-schedule strategies.
Using QSP can provide a significant impact to how clinical trials are designed and executed, and ultimately how SLE is treated. Presenter: Dr. Kathleen Morgan-Kehr, Associate Director of QSP Moderator: Saumitra Rahatekar, Business Development Account Executive